Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.

BACKGROUND & AIMS Recent research indicates that severe muscular depletion (sarcopenia) is frequent in cancer patients and linked to cachexia and poor survival. Our aim was to investigate if measures of skeletal muscle hold prognostic information in advanced non-small cell lung cancer (NSCLC). METHODS We included NSCLC patients with disease stage IIIB/IV, performance status 0-2, enrolled in three randomised trials of first-line chemotherapy (n = 1305). Computed tomography (CT) images obtained before start of treatment were used for body composition analyses at the level of the third lumbar vertebra (L3). Skeletal muscle mass was assessed by measures of the cross sectional muscle area, from which the skeletal muscle index (SMI) was obtained. Skeletal muscle radiodensity (SMD) was measured as the mean Hounsfield unit (HU) of the measured muscle area. A high level of mean HU indicates a high SMD. RESULTS Complete data were available for 734 patients, mean age 65 years. Both skeletal muscle index (SMI) and muscle radiodensity (SMD) varied largely. Mean SMI and SMD were 47.7 cm2/m2 and 37.4 HU in men (n = 420), 39.6 cm2/m2 and 37.0 HU in women (n = 314). Multivariable Cox regression analyses, adjusted for established prognostic factors, showed that SMD was independently prognostic for survival (Hazard ratio (HR) 0.98, 95% CI 0.97-0.99, p = 0.001), whereas SMI was not (HR 0.99, 95% CI 0.98-1.01, p = 0.329). CONCLUSION Low SMD is associated with poorer survival in advanced NSCLC. Further research is warranted to establish whether muscle measures should be integrated into routine practice to improve prognostic accuracy.

[1]  S. Kaasa,et al.  Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Lobo,et al.  The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. , 2015, Clinical nutrition.

[3]  R. Bremnes,et al.  Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group , 2012, British Journal of Cancer.

[4]  V. Baracos,et al.  Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies , 2013, Cancer.

[5]  J. Ross,et al.  Intramyocellular lipid droplets increase with progression of cachexia in cancer patients , 2011, Journal of cachexia, sarcopenia and muscle.

[6]  M. V. Van Vledder,et al.  Body composition and outcome in patients undergoing resection of colorectal liver metastases , 2012, The British journal of surgery.

[7]  F. Jardin,et al.  Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2014, Leukemia & lymphoma.

[8]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[9]  V. Baracos,et al.  Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. , 2016, Seminars in cell & developmental biology.

[10]  Y. Sakamoto,et al.  Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer , 2015, Annals of Surgical Oncology.

[11]  Stephanie Daignault,et al.  Worsening Central Sarcopenia and Increasing Intra-Abdominal Fat Correlate with Decreased Survival in Patients with Adrenocortical Carcinoma , 2012, World Journal of Surgery.

[12]  L. Mccargar,et al.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Michael J. Englesbe,et al.  Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma , 2011, Annals of Surgical Oncology.

[14]  K. Fearon.  Cancer cachexia: developing multimodal therapy for a multidimensional problem. , 2008, European journal of cancer.

[15]  Tony Reiman,et al.  Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. , 2010, The American journal of clinical nutrition.

[16]  K. Fearon,et al.  Low Muscularity and Myosteatosis Is Related to the Host Systemic Inflammatory Response in Patients Undergoing Surgery for Colorectal Cancer , 2016, Annals of surgery.

[17]  Lisa Martin,et al.  Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer , 2009, Clinical Cancer Research.

[18]  J. Baeyens,et al.  Sarcopenia: European consensus on definition and diagnosis , 2010, Age and ageing.

[19]  J. Zmuda,et al.  Epidemiology of myosteatosis , 2010, Current opinion in clinical nutrition and metabolic care.

[20]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[21]  Stanley Heshka,et al.  Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. , 2004, Journal of applied physiology.

[22]  D. McMillan,et al.  Use of Inflammatory Markers to Guide Cancer Treatment , 2011, Clinical pharmacology and therapeutics.

[23]  J. W. Kim,et al.  Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy , 2015, Supportive Care in Cancer.

[24]  W. John,et al.  Cancer Management and Research Dovepress a Comprehensive Review of Nongenetic Prognostic and Predictive Factors Influencing the Heterogeneity of Outcomes in Advanced Non-small-cell Lung Cancer , 2022 .

[25]  G. Biolo,et al.  Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". , 2010, Clinical nutrition.

[26]  E. Bruera,et al.  Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. , 2012, Journal of pain and symptom management.

[27]  Rebecca M. Dodson,et al.  Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies , 2013, Journal of Gastrointestinal Surgery.

[28]  R Ross,et al.  Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. , 2000, Journal of applied physiology.

[29]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[30]  Maren S Fragala,et al.  Muscle Quality in Aging: a Multi-Dimensional Approach to Muscle Functioning with Applications for Treatment , 2015, Sports Medicine.

[31]  V. Baracos,et al.  Measurement of skeletal muscle radiation attenuation and basis of its biological variation , 2014, Acta physiologica.

[32]  K. Kinzig,et al.  The role of insulin resistance in the development of muscle wasting during cancer cachexia , 2011, Journal of cachexia, sarcopenia and muscle.

[33]  R. Bremnes,et al.  Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity , 2007, British Journal of Cancer.

[34]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[35]  Y. Sakamoto,et al.  Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer , 2015, PloS one.

[36]  Masataka Taguri,et al.  Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. , 2015, Journal of hepatology.

[37]  H. Wakelee,et al.  Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594 , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  R. Govindan,et al.  Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.